FTC Continues To Target Pharmaceutical Mergers

The Federal Trade Commission has often stated that merger analysis requires more than a simplistic determination that high market concentration leads to anti-competitive effects.[1] Still, the antitrust agencies have consistently considered...

Already a subscriber? Click here to view full article